Related Experiment Video
Updated: Jul 3, 2026
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
Screening and identification of an anti-PD-1 nanobody with antitumor activity
Yanting Zhang1, Shaoqi Yang1, Dan Jiang2
1General Hospital of Ningxia Medical University, Yinchuan, China.
Abstract:
Blocking of PD-1 or PD-L1 with corresponding antibody to enhance T cell response and mediate antitumor activity has been successfully applied in clinical practice. Several immune checkpoint inhibitors including monoclonal antibodies targeting PD-1 have been approved by the Food and Drug Administration (FDA) in cancer immunotherapy. However, the application of traditional antibodies has limited due to their drawbacks of large molecular weight and low tissue penetration. As the high specificity and strong tissue penetration of nanobodies (Nbs), efforts have been taken to develop Nbs for cancer therapy. Herein, we aim to screen a specific Nb against human PD-1 derived from a naïve camel Nb phage display library and further study its biological characteristic and anti-tumor activity. Finally, an anti-PD-1 Nb with high specificity and affinity was screened and generated, its cytotoxicity and antitumor effect was also confirmed in vitro and vivo. All of these indicate that the anti-PD-1 Nb may provide an alternative and appealing therapeutic agent for cancer immunotherapy.
Insights
Researchers developed a novel nanobody targeting PD-1 for cancer immunotherapy. This nanobody shows high specificity and potent antitumor activity, offering a promising alternative to traditional antibodies.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Immune checkpoint inhibitors like antibodies targeting PD-1 are established cancer therapies.
- Traditional antibodies face limitations in molecular weight and tissue penetration.
- Nanobodies (Nbs) offer high specificity and tissue penetration, making them suitable for cancer therapy.
Purpose of the Study:
- To screen and develop a specific nanobody against human PD-1.
- To evaluate the biological characteristics and antitumor activity of the anti-PD-1 nanobody.
Main Methods:
- Screening of a naive camel nanobody phage display library for anti-PD-1 binders.
- Characterization of nanobody specificity, affinity, and biological activity.
- In vitro and in vivo assessment of antitumor effects.
Main Results:
- A high-specificity and high-affinity anti-PD-1 nanobody was successfully screened and generated.
- The nanobody demonstrated significant cytotoxicity and antitumor effects in both in vitro and in vivo models.
Conclusions:
- The developed anti-PD-1 nanobody is a potential therapeutic candidate for cancer immunotherapy.
- Nanobodies present a promising alternative to conventional antibodies due to their favorable properties.
More Related Videos
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
07:04Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
